Suppliers and packagers for gleevec

gleevec

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novartis	GLEEVEC	imatinib mesylate	TABLET;ORAL	021588	NDA	Novartis Pharmaceuticals Corporation	0078-0401-34	90 TABLET in 1 BOTTLE (0078-0401-34)	2001-05-15
Novartis	GLEEVEC	imatinib mesylate	TABLET;ORAL	021588	NDA	Novartis Pharmaceuticals Corporation	0078-0649-13	3 BLISTER PACK in 1 CARTON (0078-0649-13) / 10 TABLET in 1 BLISTER PACK (0078-0649-26)	2014-12-23
Novartis	GLEEVEC	imatinib mesylate	TABLET;ORAL	021588	NDA	Novartis Pharmaceuticals Corporation	0078-0649-30	30 TABLET in 1 BOX, UNIT-DOSE (0078-0649-30)	2014-12-23

Suppliers for the Pharmaceutical Drug: GLEEVEC

Last updated: July 28, 2025

Introduction

Gleevec, known generically as imatinib mesylate, is a groundbreaking targeted cancer therapy developed by Novartis. Approved initially by the FDA in 2001 for chronic myeloid leukemia (CML), Gleevec revolutionized oncology treatment by offering a precision approach that inhibits specific abnormal proteins responsible for uncontrolled cell proliferation. Its success has spurred a complex global supply ecosystem involving multiple manufacturers, suppliers of raw materials, contract manufacturing organizations (CMOs), and distribution channels. This report explores the current landscape of Gleevec suppliers, highlighting key constituents, supply chain dynamics, and implications for stakeholders.

---

Manufacturers and Originators

Novartis AG

As the patent holder and original manufacturer of Gleevec, Novartis controls significant aspects of the supply chain. The Swiss pharmaceutical giant has established manufacturing facilities primarily in Europe and the United States, adhering to stringent Good Manufacturing Practice (GMP) standards. These facilities oversee the synthesis, formulation, and packaging of Gleevec, ensuring consistent quality and supply.

Generic Manufacturers

Following patent expiration in 2015, a wave of generic manufacturers gained approval to produce imatinib, leading to increased global supply options and reduced prices. Key players include:

• Natco Pharma (India): Among the first to receive approval for generic imatinib, expanding access in emerging markets.
• Zydus Cadila (India): Produces generic versions with high bioequivalence standards.
• Cipla (India): Offers affordable imatinib formulations for developing countries.
• Sun Pharma (India): Developed generic imatinib for various markets.
• Sankyo, Mylan, and Apotex: Also produce generic versions, often through licensing agreements or independently after patent expiry.

Note: The U.S. FDA has approved multiple generic versions, increasing supply diversity and affordability.

---

Raw Material Suppliers

The production of imatinib involves complex chemical synthesis requiring high-quality raw materials, including:

• Intermediate chemicals: These include substituted pyrimidines, amino acids, and heterocyclic compounds.
• Key starting materials: Sourced from specialized chemical suppliers that produce APIs (active pharmaceutical ingredients) and intermediates compliant with GMP.

Major raw material suppliers tend to be large chemical manufacturers in India, China, and Europe, such as:

• Hikal Ltd. (India): Supplies chemical intermediates.
• Shandong Asymchem Co., Ltd. (China): Produces key intermediates for pharmaceutical synthesis.
• BASF and Evonik (Germany): Provide specialty chemicals and raw ingredients.

Supply chain disruptions in raw materials can significantly impact Gleevec manufacturing, especially given the reliance on chemical suppliers in Asia.

---

Contract Manufacturing Organizations (CMOs)

Multiple CMOs specialize in the formulation, filling, and packaging of Gleevec, either on behalf of Novartis or generic companies. Notable CMOs include:

• Siegfried AG (Switzerland): Used for formulation and packaging of original Gleevec products.
• Famar (Greece): Offers manufacturing services for generic imatinib formulations.
• Hetero Labs (India): Engaged in formulation, blending, and packaging of generic drugs.

CMO engagement allows flexibility in capacity scaling, reduces time-to-market, and minimizes regulatory bottlenecks.

---

Distribution and Supply Chain Channels

Gleevec's distribution network spans healthcare providers, pharmacies, hospital systems, and specialty pharmacies worldwide. Due to its critical role in cancer treatment, supply chain resilience is paramount. The following factors influence distribution:

• Regulatory approvals: Varying approvals across countries influence market access and supply stability.
• Pricing and reimbursement policies: Affect the availability of both branded and generic versions.
• Global manufacturing capacity: Determined by alliances, licensing, and regional manufacturing hubs.

In emerging markets, local distributors and regional regulatory bodies facilitate access, often utilizing imported generics to meet demand.

---

Supply Challenges and Market Dynamics

The global supply of Gleevec has faced several challenges:

• Patent expirations: Led to an influx of generics, increasing affordability but creating competition.
• Raw material shortages: Disruption in chemical supply chains, notably during COVID-19, emphasized vulnerabilities.
• Manufacturing capacity constraints: Periodic shortages have prompted manufacturers to optimize capacities and diversify suppliers.
• Regulatory hurdles: Variability in regulatory landscapes can delay approvals and market entry for generic versions.

Meanwhile, Novartis maintains control over original formulations, often through strategic manufacturing and licensing agreements.

---

Key Stakeholders and Strategic Considerations

• Novartis: Continues to supply branded Gleevec, leveraging manufacturing expertise and global distribution networks.
• Generic manufacturers: Expand access and reduce costs; their market share varies by region.
• Raw material suppliers: Critical in maintaining supply stability; quality and compliance are safeguards against contamination and defects.
• Contract manufacturers: Provide operational flexibility, especially for regional or volume-specific demands.

Effective supply chain management involves balancing innovation, cost, and access, with a focus on quality assurance.

---

Implications for Industry and Business Professionals

Understanding the Gleevec supply landscape aids in strategic decision-making surrounding procurement, regulatory engagement, and competitive positioning. Manufacturers and healthcare providers must maintain supply chain agility to navigate challenges, especially amid geopolitical tensions and global disruptions.

---

Key Takeaways

• Global manufacturing ecosystem: Gleevec's supply involves a combination of originator and multiple generic manufacturers, with an extensive network of raw material suppliers and CMOs.
• Patent expiration impact: Facilitated a shift toward generics, increasing supply options, but also introducing competition and price sensitivity.
• Supply chain vulnerabilities: Dependence on chemical intermediates from Asia poses risks that require strategic diversification.
• Regulatory influence: Approval pathways and regional policies significantly affect market availability.
• Market strategy: Engagement with reliable suppliers, proactive inventory management, and compliance are crucial for stakeholder success.

---

FAQs

1. Who are the primary manufacturers of Gleevec today?
Original formulations are produced predominantly by Novartis. Post-patent expiration, several Indian generic manufacturers such as Natco, Cipla, Zydus Cadila, and Sun Pharma supply generic imatinib. Some European and U.S. companies also produce authorized generics.

2. What raw materials are involved in manufacturing Gleevec?
The synthesis involves complex intermediates, including substituted pyrimidines, amino acids, and heterocyclic compounds sourced mainly from chemical suppliers in India, China, and Europe.

3. How has patent expiration affected Gleevec's supply chain?
Patent expiry has enabled multiple generics to enter the market, increasing supply volume, reducing costs, and improving global access, especially in developing countries.

4. What are the main challenges facing Gleevec supply chain today?
Challenges include raw material shortages, manufacturing capacity limitations, regulatory hurdles, and geopolitical factors affecting Asian suppliers.

5. How do supply chain disruptions impact Gleevec availability?
Disruptions can lead to shortages, affecting treatment continuity for patients. Manufacturers mitigate risks through regional production, supplier diversification, and inventory management.

---

References

1. Novartis. (2022). Gleevec (imatinib) product information.
2. U.S. Food and Drug Administration. (2015). Approved generics for Gleevec.
3. Indian FDA approvals of generic imatinib. (2016-2022).
4. Chemical suppliers to the pharmaceutical industry. (2021). Market research reports.
5. Supply chain analyses in oncology drugs. (2022). Industry insights.

---

By analyzing the Gleevec supply landscape, stakeholders can make strategic, informed decisions to optimize access, ensure continuity, and anticipate future market shifts.